Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Khater

Ophthalmology Lubbock, TX Medical Doctor

NPI 1669476255 CMS profile 1065342

5109 80Th St, Lubbock, TX 79424

Open in the dashboard

General payments

$19,012

446 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Khater of Lubbock, TX is reported in the CMS Open Payments database as having received $19,012 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,485 78
2024 General $2,080 55
2023 General $2,046 64
2022 General $1,723 47
2021 General $2,180 63
2020 General $1,902 49
2019 General $6,597 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Khater
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Timothy Khater were reported at $2,485. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Timothy Khater Ophthalmology median Middle half National median
2019 $6,597 $258 $104–$655 $163
2020 $1,902 $126 $45–$321 $114
2021 $2,180 $205 $76–$534 $132
2022 $1,723 $266 $100–$678 $149
2023 $2,046 $308 $117–$745 $160
2024 $2,080 $340 $127–$846 $164
2025 $2,485 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Surgical Vision, Inc. $5,018 83 payments
  2. Alcon Vision LLC $3,265 47 payments
  3. Glaukos Corporation $2,938 45 payments
  4. Allergan Inc. $1,421 64 payments
  5. Ivantis, Inc $1,067 18 payments
  6. Ocular Therapeutix, Inc. $1,012 46 payments
  7. AbbVie, Inc. $910 29 payments
  8. Sight Sciences, Inc. $678 28 payments
  9. Bausch & Lomb Americas Inc. $328 11 payments
  10. RxSight Inc $253 5 payments
  11. Other $2,122 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,798 428 payments
  2. Travel and Lodging $3,280 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $562 8 payments
  4. Consulting Fee $300 3 payments
  5. Honoraria $50 1 payment
  6. Entertainment $23 1 payment
Products named General payments · program years 2019–2025
  1. Tecnis Symfony IOL $2,127 16 payments
  2. Tecnis Multifocal Family of 1-piece IOLS $2,100 14 payments
  3. Tecnis 1-piece IOL $1,965 13 payments
  4. iStent inject Trabecular Micro-Bypass Stent System $1,718 12 payments
  5. iStent Trabecular Micro-Bypass Stent System $1,425 5 payments
  6. VERITAS Vision System $1,322 30 payments
  7. HYDRUS Microstent $1,057 15 payments
  8. Hydrus $721 12 payments
  9. DEXTENZA $712 43 payments
  10. Tecnis IOL $672 13 payments
  11. Other $14,025 399 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

3,246

Median for Ophthalmology: 891

Drug cost

$711,874

Median for Ophthalmology: $68,233

Branded share of claims

31.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxervate Cenegermin-Bkbj Brand 13 $368,515
Lumigan Bimatoprost Brand 272 $139,295
Prednisolone Acetate Generic 735 $36,269
Restasis Cyclosporine Brand 36 $35,261
Vyzulta Latanoprostene Bunod Brand 40 $17,040
Xiidra Lifitegrast Brand 13 $15,788
Cyclosporine Generic 19 $14,427
Moxifloxacin Moxifloxacin Hcl Brand 420 $9,999
Combigan Brimonidine Tartrate/Timolol Brand 29 $9,775
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 53 $8,357

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$474,197

Medicare's payments for the services billed

Medicare patients

1,120

Average age 75

Services billed

4,161

679 women, 441 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 31%
Ischemic heart disease 30%
Chronic kidney disease 20%
Atrial fibrillation 18%
Depression 16%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DEXTENZA
  • Ocular Therapeutix, Inc. $175
$175 — —
LUMIGAN
  • AbbVie, Inc. $61
$61 272 —
BOTOX
  • AbbVie, Inc. $43
$43 — —
Sucraid
  • QOL Medical, LLC $38
$38 — —
ILUVIEN
  • Alimera Sciences, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record